This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
- Pretargeted Imaging and Therapy
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
- Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
- Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
- Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
- Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein
- Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
- Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- Residualizing Iodine Markedly Improved Tumor Targeting Using Bispecific Antibody-Based Pretargeting
- A Phase I Trial Combining High-Dose 90Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
- The Direct Route May Not Be the Best Way to Home
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Amplification Targeting: A Modified Pretargeting Approach with Potential for Signal Amplification--Proof of a Concept
- Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
- Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
- Targeting of 125I-Labeled B Lymphocyte Stimulator
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- Tumor Pretargeting in Mice Using 99mTc-Labeled Morpholino, a DNA Analog
- A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
- Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies
- Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs